193 related articles for article (PubMed ID: 12904106)
1. Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era.
Jacobson TA
Expert Opin Drug Saf; 2003 May; 2(3):269-86. PubMed ID: 12904106
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
Williams D; Feely J
Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
[TBL] [Abstract][Full Text] [Related]
3. [Statins in patients with renal failure--the current therapeutic status].
Filipiak KJ; Zawadzka-Byśko M
Przegl Lek; 2005; 62 Suppl 2():51-4. PubMed ID: 16623120
[TBL] [Abstract][Full Text] [Related]
4. [Myotoxicity and rhabdomyolisis due to statins].
Banga JD
Ned Tijdschr Geneeskd; 2001 Dec; 145(49):2371-6. PubMed ID: 11770264
[TBL] [Abstract][Full Text] [Related]
5. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
Evans M; Rees A
Drug Saf; 2002; 25(9):649-63. PubMed ID: 12137559
[TBL] [Abstract][Full Text] [Related]
6. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).
Igel M; Sudhop T; von Bergmann K
Eur J Clin Pharmacol; 2001 Aug; 57(5):357-64. PubMed ID: 11599653
[TBL] [Abstract][Full Text] [Related]
7. Comparative tolerability of the HMG-CoA reductase inhibitors.
Farmer JA; Torre-Amione G
Drug Saf; 2000 Sep; 23(3):197-213. PubMed ID: 11005703
[TBL] [Abstract][Full Text] [Related]
8. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.
Chatzizisis YS; Koskinas KC; Misirli G; Vaklavas C; Hatzitolios A; Giannoglou GD
Drug Saf; 2010 Mar; 33(3):171-87. PubMed ID: 20158283
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological interactions of statins.
Paoletti R; Corsini A; Bellosta S
Atheroscler Suppl; 2002 May; 3(1):35-40. PubMed ID: 12044584
[TBL] [Abstract][Full Text] [Related]
10. Clinically relevant differences between the statins: implications for therapeutic selection.
Chong PH; Seeger JD; Franklin C
Am J Med; 2001 Oct; 111(5):390-400. PubMed ID: 11583643
[TBL] [Abstract][Full Text] [Related]
11. Safety considerations for statins.
Bolego C; Baetta R; Bellosta S; Corsini A; Paoletti R
Curr Opin Lipidol; 2002 Dec; 13(6):637-44. PubMed ID: 12441888
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
Rätz Bravo AE; Tchambaz L; Krähenbühl-Melcher A; Hess L; Schlienger RG; Krähenbühl S
Drug Saf; 2005; 28(3):263-75. PubMed ID: 15733030
[TBL] [Abstract][Full Text] [Related]
13. Statin-fibrate combination therapy.
Shek A; Ferrill MJ
Ann Pharmacother; 2001; 35(7-8):908-17. PubMed ID: 11485144
[TBL] [Abstract][Full Text] [Related]
14. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].
Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):41-5. PubMed ID: 16541751
[TBL] [Abstract][Full Text] [Related]
15. Risk for myopathy with statin therapy in high-risk patients.
Ballantyne CM; Corsini A; Davidson MH; Holdaas H; Jacobson TA; Leitersdorf E; März W; Reckless JP; Stein EA
Arch Intern Med; 2003 Mar; 163(5):553-64. PubMed ID: 12622602
[TBL] [Abstract][Full Text] [Related]
16. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor.
Kajinami K; Takekoshi N; Saito Y
Cardiovasc Drug Rev; 2003; 21(3):199-215. PubMed ID: 12931254
[TBL] [Abstract][Full Text] [Related]
17. Low myopathy rates associated with statins as monotherapy or combination therapy with interacting drugs in a group model health maintenance organization.
Shanahan RL; Kerzee JA; Sandhoff BG; Carroll NM; Merenich JA
Pharmacotherapy; 2005 Mar; 25(3):345-51. PubMed ID: 15843281
[TBL] [Abstract][Full Text] [Related]
18. [Adverse effects of statins].
Andréjak M; Gras V; Massy ZA; Caron J
Therapie; 2003; 58(1):77-83. PubMed ID: 12822204
[TBL] [Abstract][Full Text] [Related]
19. [Severe muscle disorders associated with statins: analysis of cases notified in France up to the end of February 2002 and data concerning the risk profile of cerivastatin].
Andréjak M; Gras V; Caron J
Therapie; 2005; 60(3):299-304. PubMed ID: 16128274
[TBL] [Abstract][Full Text] [Related]
20. Statin-associated myopathy.
Hamilton-Craig I
Med J Aust; 2001 Nov; 175(9):486-9. PubMed ID: 11758079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
